Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study

Fig. 3

Receiver operating characteristic curve analyses for the prediction of CDAI nonremission at 6 months of biologic therapy. a infliximab. b tocilizumab. c abatacept. CDAI clinical disease activity index, AUC area under the curve, CI confidence interval, PPV positive predictive value, NPV negative predictive value. “Positive” means CDAI nonremission at 6 months of biologic therapy

Back to article page